UCLA researchers use lipid nanoparticles to insert full CFTR gene into airway cells, restoring function and opening new ...
Genetic medicine is rapidly transforming the landscape of cancer research, offering novel strategies for treating malignancies beyond the capabilities of ...
One of the most promising is its cardiovascular disease therapy candidate CTX310, a single-treatment gene therapy that has ...
MarketBeat on MSN
CRISPR Therapeutics gains after earnings as pipeline hope grows
CRISPR Therapeutics AG (NASDAQ: CRSP) stock is up more than 12% after the gene editing pioneer reported its Q4 2025 earnings ...
The firm will provide manufacturing and regulatory support as UW prepares an IND submission for its GD2 CAR T-cell therapy.
YolTech Therapeutics Announces Positive Interim Data on YOLT-202 for the Treatment of Alpha-1 Antitrypsin Deficiency ...
Henry Ford Health has treated the first Michigan patient outside clinical trials with Roctavian, the newly approved gene ...
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
At the recent Innovation @ Penn program in San Francisco, leaders debated how gene editing, adaptable platforms and new regulatory processes could move personalized care beyond single-patient wins.
Get a closer look at the biotech ophthalmology landscape to discover exactly how companies are approaching the treatment of eye diseases.
Jacob Funds, a mutual fund company, released its fourth-quarter 2025 investor letter. A copy of the same can be downloaded here.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results